LimmaTech Biologics is an early-stage company based in Switzerland. We are developing a novel expression platform – the Custom Glycan Platform - for the manufacturing of first-in-class therapeutic glycoproteins. The Custom Glycan Platform enables fast, robust and simple production of proteins with tailored and homogenous glycosylation patterns. This allows to obtain more safe and efficacious products. We are currently focusing on monoclonal antibodies which thanks to the glycan profile will be better clinical outcomes.